Website News and Research

RSS

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

Early diagnosis of interstitial cystitis can improve quality of life

October is interstitial cystitis (IC) awareness month and this year's campaign is dedicated to fighting discrimination.

5 Oct 2010

Study finds BRACAnalysis vital for triple negative breast cancer patients

Myriad Genetics, Inc. announced today that results from a preliminary study indicate that BRCA germline mutations occur at a high frequency in women with triple negative breast cancer, sufficiently high enough to justify screening of all women with TNBC.

5 Oct 2010

CHI submits comments to FDA CDRH 510(k) Working Group Preliminary Report and Recommendations

California Healthcare Institute today submitted formal comments to the U.S. Food and Drug Administration (FDA) regarding the Center for Devices and Radiological Health 510(k) Working Group Preliminary Report and Recommendations, which could transform the 510(k) regulatory process for new medical devices, greatly affecting innovation and public health in California. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

5 Oct 2010

Health law's insurance plans for pre-existing conditions are slow to enroll; 3M to drop early retiree coverage

The Associated Press: "It's a centerpiece of President Barack Obama's health care remake, a lifeline available right now to vulnerable people whose medical problems have made them uninsurable. But the Pre-Existing Condition Insurance Plan started this summer isn't living up to expectations. Enrollment lags in many parts of the country. People who could benefit may not be able to afford the premiums. Some state officials who run their own "high-risk pools" have pointed out potential problems" (Alonso-Zaldivar, 10/3).

4 Oct 2010

LC Luxuries announces acquisition of domain name CannaCare.com

LC LUXURIES LIMITED today announced that it has acquired the domain name CannaCare.com and will begin developing CannaCare.com as its nationwide physician marketing engine as it relates to the cannabis industry. Development is underway and the Company anticipates the site operational by the end of the year. Bonni Goldstein, MD, a board member for LC Luxuries Limited, will be materially involved with the content and direction of CannaCare.com.

4 Oct 2010

First Edition: October 4, 2010

In this Kaiser Health News column, Louis Saccoccio, executive director of the National Health Care Anti-Fraud Association, makes a case for including health plans' investments in fraud-fighting activities in the medical loss ratio definition. "While the federal government is investing heavily in anti-fraud efforts, private insurers should be given the incentive to do the same. Only through a cooperative and concentrated effort to root out health care fraud can we effectively protect Americans' quality of health care" (Kaiser Health News).

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Benitec Limited, a leading Australian based company specialising in RNA interference (RNAi) technology is pleased to announce the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

4 Oct 2010

Fred Hutchinson Center offers research-based tip sheets on breast cancer

Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship.

4 Oct 2010

Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium

Array BioPharma Inc. today announced positive interim results of its novel, oral HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in patients with advanced cancer.

4 Oct 2010

HHS consumer website adds new features; health law provisions affecting open season

HealthCare.Gov, the consumer health care insurance website run by the federal government, unveiled a slew of new features this morning. Consumers can find pricing information for 4,400 individual and family health plans offered by more than 225 insurance carriers, Plan information will be updated monthly, said Todd Park, HHS chief technology officer.

4 Oct 2010

Bionovo enters definitive agreement to raise $3.0 million in registered direct offering

Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.

4 Oct 2010

Health insurance prices, restrictions now on federal consumer website

Kaiser Health News staff writer Jessica Marcy talked with Todd Park, the chief technology officer of the Department of Health and Human Services, and Karen Pollitz, who heads the consumer support division at HHS Office of Consumer Information and Insurance Oversight, about the detailed health plan cost and benefits information unveiled today on Healthcare.gov.

1 Oct 2010

GHI won't compromise PEPFAR, Global AIDS Coordinator says at House Foreign Affairs' Committee hearing

During a House Committee on Foreign Affairs' hearing on the future of PEPFAR Wednesday, U.S. Global AIDS Coordinator Ambassador Eric Goosby assured lawmakers that the decision by President Barack Obama to make PEPFAR part of the president's Global Health Initiative (GHI) would not compromise "the widely praised plan," CQ HealthBeat reports.

1 Oct 2010

Neb. insurer launches pilot program to cut costs, improve health; W.Va. Medicaid official defends no-bid contract

Lincoln Journal Star: Blue Cross and Blue Shield of Nebraska, the state's largest health insurer, is establishing a new pilot program that seeks to give doctors better patient information so that they can deal more effectively with patients' needs and help lower costs. The pilot will use a web-based program that officials hope can take disparate medical records and produce "tailored patient checklists" that doctors can use.

1 Oct 2010

HIV/AIDS researchers, government officials track progress, forecast challenges for HIV vaccine development

More than 1,000 researchers, government officials and advocates are gathering in Atlanta this week to discuss the progress and future challenges in the development of a vaccine that protects against HIV, FierceVaccines reports (Carroll, 9/29). The AIDS Vaccine 2010 meeting, which kicked off Tuesday, will run through Friday, according to the website for the meeting (undated).

1 Oct 2010

ACGME approves graduated standards for duty hours for residents training in accredited teaching institutions

The Accreditation Council for Graduate Medical Education (ACGME) Board of Directors has approved a set of requirements that are a comprehensive approach to patient care, quality improvement, supervision, professionalism, transitions in care, and resident well-being. Included are graduated standards for duty hours for the nation's 111,000 residents training in ACGME accredited teaching institutions. The new standards will go into effect in July 2011.

30 Sep 2010

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010. The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and is available on the Company's website.

30 Sep 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

Website News and Research

Neuraltus achieves last patient out for NP001, NP002 studies

Early diagnosis of interstitial cystitis can improve quality of life

Study finds BRACAnalysis vital for triple negative breast cancer patients

CHI submits comments to FDA CDRH 510(k) Working Group Preliminary Report and Recommendations

Health law's insurance plans for pre-existing conditions are slow to enroll; 3M to drop early retiree coverage

LC Luxuries announces acquisition of domain name CannaCare.com

First Edition: October 4, 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Fred Hutchinson Center offers research-based tip sheets on breast cancer

Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium

HHS consumer website adds new features; health law provisions affecting open season

Bionovo enters definitive agreement to raise $3.0 million in registered direct offering

Health insurance prices, restrictions now on federal consumer website

GHI won't compromise PEPFAR, Global AIDS Coordinator says at House Foreign Affairs' Committee hearing

Neb. insurer launches pilot program to cut costs, improve health; W.Va. Medicaid official defends no-bid contract

HIV/AIDS researchers, government officials track progress, forecast challenges for HIV vaccine development

ACGME approves graduated standards for duty hours for residents training in accredited teaching institutions

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News